Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

Trial Profile

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors AbbVie; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 31 Oct 2013 Planned number of patients changed from 38 to 39 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top